This prospective, multicenter, real-world observational cohort study will describe phenotypic profiles, patient characteristics, and treatments in adults with stable chronic obstructive pulmonary disease (COPD). The profiles observed in the current cohort will be compared with those of patients recruited between 2005 and 2018 in the previous COPD-BPCO 1 cohort. Patients will be followed for at least 3 years as part of routine care, with no study-specific visit or treatment.
COPD is a heterogeneous disease, and patient characteristics may be associated with prognosis and treatment response. The previous Initiative BPCO cohort recruited 1,720 subjects between 2005 and 2018 and identified clinically relevant COPD phenotypes, including subgroups associated with mortality risk. Because diagnostic strategies, risk factors, comorbidity management, and COPD treatments have evolved, this new prospective dynamic cohort will assess whether current COPD phenotypes differ from those previously identified and whether classification and regression tree (CART) algorithms developed in the previous cohort remain applicable. Data will be collected during routine care from hospital pulmonology centers in France. Baseline and follow-up data may include demographics, risk factors, comorbidities, usual treatments, patient-reported questionnaires, pulmonary function, arterial blood gases, 6-minute walk test, imaging, biology results, exacerbations, and mortality status.
Study Type
OBSERVATIONAL
Enrollment
500
Patients will be managed according to usual care at the investigator's discretion. The study does not assign any treatment, medicinal product, or medical device.
Chu Bordeaux
Bordeaux, France
RECRUITINGChu Lille
Lille, France
RECRUITINGChu Lille
Lille, France
RECRUITINGChu Nancy-Brabois
Nancy, France
RECRUITINGHopital Cochin
Paris, France
RECRUITINGChu Reims
Reims, France
RECRUITINGChu Saint Etienne
Saint-Etienne, France
RECRUITINGIdentification and description of COPD phenotypic profiles
COPD phenotypic subgroups will be defined using unsupervised clustering and described according to patient characteristics, treatments, pulmonary function, symptoms, exacerbations, clinically important deterioration, and mortality
Time frame: Baseline and up to 3 years
Comparison of phenotypic profiles with the previous COPD-BPCO 1 cohort
Baseline and up to 3 years
Time frame: Current profiles will be compared with those observed in the previous cohort recruited between 2005 and 2018.
Prognosis of current patients compared with the previous cohort
Prognosis will be explored using mortality at 3 years, exacerbations, pulmonary function, dyspnea, health status, treatment modifications, and clinically important deterioration
Time frame: 3 years
Applicability of previously developed CART algorithms
Classification and regression tree algorithms developed from COPD-BPCO 1 will be applied to the new cohort and, if needed, new classification trees will be developed.
Time frame: Through study completion, an average of 3 years
Adverse events
Number and detailed description of adverse events collected as part of the study, although no adverse event related to the study itself is expected.
Time frame: Through study completion, an average of 3 years
José GARCIA-MACE
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.